Journal of Allergy & Therapy

Jörg Schnitker

Publications

• Research Article
  Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet is well Tolerated in Children, Adolescents and Adults in Real Life Application-A Non-Interventional Observational Study
  Author(s): Christine Gronke, Hendrik Wolf, Jörg Schnitker and Eike WüstenbergChristine Gronke, Hendrik Wolf, Jörg Schnitker and Eike Wüstenberg
  
  Background: Efficacy and safety of the SQ-standardised grass allergy immunotherapy tablet (GRAZAX®) has been reported in a large number of randomised, controlled clinical trials in children and adults performed in Europe and the US. GRAZAX® became available for routine treatment in children from 5 years of age in Germany and Austria in 2008.To examine the safety and tolerability of GRAZAX® in patients that were less highly selected as in the controlled trials we performed an open label, uncontrolled, non-interventional study in children and adults who were routinely treated in allergists´ offices. Materials and methods: Patients with allergic rhinoconjunctivitis with or without asthma were treated with GRAZAX® and observed for 3-4 visits every 3 months with the last visit after the first grass pollen season. Adverse seasons before and during therapy. .. View More»
  DOI: 10.4172/2155-6121.1000146

  Abstract PDF